Digital Pharma: AZ launches its first UK iPhone app
pharmafile | December 8, 2010 | News story | Medical Communications | Apple, AstraZeneca, Digital Pharma blog, apps, ipad, iphone
AstraZeneca has launched an iPhone app to provide UK healthcare professionals with information on genetic tests for lung cancer.
The company has not been in a rush to produce mobile applications and the EGRF Mutation Testing app is only its second, and the first it has released for the UK.
The app aims to raise awareness among geneticists, pathologists and medical oncologists of epidermal growth factor receptor (EGFR) gene testing in non-small cell lung cancer (NSCLC).
In July this year AstraZeneca’s Iressa (gefitinib) was recommended by NICE as a first-line treatment for locally advanced or metastatic NSCLC in patients who test positive for the EGFR tyrosine kinase (EGFR-TK) mutation.
AstraZeneca UK marketing company president Mark Jones said the free app would “provide useful educational information to ensure that all eligible patients receive an EGFR test”.
The pharma company has also launched www.egfr-info.co.uk, a website for UK healthcare professionals that provides more information on EFGR testing.
Its accompanying iPhone app includes information on EGFR-mutation testing, when and how to carry it out, a case study to highlight a patient’s journey through diagnosis, and management options.
The app is also availalble in an version for Apple’s iPad and was produced by Creative Lynx, the Manchester, UK-based agency behind the UK psoriasis iPhone app launched by Janssen over the summer.
AstraZeneca joined the ranks of big pharma companies who have released an iPhone app in October this year with its US Enhance oncology app.
This provides educational resources and medical recommendations in areas like menopause surveillance, sexual well being and hot flushes. But requires an activation code to ensure it is only downloaded by its target users – healthcare professionals that treat breast cancer in post-menopausal women.
Dominic Tyer is web editor for Pharmafocus and InPharm.com and the author of the Digital Pharma blog He can be contacted via email, Twitter or LinkedIn.
Related Content
NICE recommends Benralizumab for Rare Form of Vasculitis
The National Institute for Health and Care Excellence (NICE) has recommended AstraZeneca’s benralizumab (Fasenra) as …
NICE approves AstraZeneca’s dual immunotherapy for advanced liver cancer
AstraZeneca has received a positive recommendation from the National Institute for Health and Care Excellence …
Purpose and people: the enduring power of brand and the evolution of employer identity
Two decades ago, terms like purpose and people were rarely at the forefront of branding …
